CliffBio
small molecule

K-TAB

POTASSIUM CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameK-TAB
Active ingredientPOTASSIUM CHLORIDE
Strength20MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2013
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

K-TAB patent cliff — loss of exclusivity — | CliffBio